{"id":"W2551516232","doi":"10.1111/apt.13852","title":"Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised <scp>GEMINI</scp> 1 trial","year":2016,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"UCB Pharma; Janssen Biotech; Genentech; Kyowa Hakko Kirin; Takeda Pharmaceuticals International; Biogen; Celgene; Novo Nordisk; Teva Pharmaceutical Industries; Gilead Sciences; ActoGeniX; Sanofi; Tillotts Pharma; Amgen; Pfizer; Ironwood Pharmaceuticals, Incorporated; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Vedolizumab; Medicine; Minimal clinically important difference; Ulcerative colitis; Placebo; Quality of life (healthcare); Internal medicine; Crohn's disease; Inflammatory bowel disease; Faecal calprotectin; Pouchitis; Population; Randomization; Clinical trial; Physical therapy; Randomized controlled trial; Disease; Calprotectin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002841566,0.0008020129,0.001981,0.0002353179,0.0002750811,0.0008487154,0.0005032243,0.001090431,0.002370338],"category_scores_gemma":[0.002921134,0.000371663,0.002177816,0.0002781362,0.0005492925,0.0005519005,0.0003426512,0.001948647,0.0002961505],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006952331,"about_ca_system_score_gemma":0.0005622695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001117648,"about_ca_topic_score_gemma":0.002336958,"domain_scores_codex":[0.998651,0.0009340746,0.0000810865,0.0001136642,0.0000939021,0.0001263709],"domain_scores_gemma":[0.9986191,0.0005521505,0.0003809684,0.0001099538,0.00007802078,0.0002598457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9585432,0.002066458,0.003239801,0.0009255723,0.003065951,0.00003928664,0.0000710001,0.0004394389,0.001919436,0.00006542533,0.0009014018,0.02872301],"study_design_scores_gemma":[0.9024806,0.06549021,0.02693106,0.0001329175,0.002746175,0.00007803036,0.0000439415,0.0005117307,0.0004098871,0.000145579,0.00100802,0.00002178208],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855203,0.01165928,0.0001525559,0.0006281864,0.0001855447,0.0004102971,0.0005679303,0.00002715114,0.0008487272],"genre_scores_gemma":[0.9936258,0.003484076,0.000310704,0.000455655,0.0001932073,0.0004332741,0.0008284131,0.000008498941,0.0006603466],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002841566,"threshold_uncertainty_score":0.01502782,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01576528093051912,"score_gpt":0.2839675321953106,"score_spread":0.2682022512647915,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}